RA Capital Management Sells 800,000 Shares of Achillion Pharmaceuticals Inc. (ACHN)

RA Capital Management, managed by Peter Kolchinsky, has sold 800,000 shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) in two transactions for about $8 apiece on June 20, 2014. Following the sale, the fund currently owns around 22.49 million shares, down from 23.37 million shares disclosed previously, according to a new filing with the U.S. Securities and Exchange Commission. The new position amasses 23.2% of the outstanding common stock.

Peter Kolchinsky

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) is a pharmaceutical company focused on solutions for the most challenging problems in infectious disease including HCV. The company has a market cap of $720.2 million.

For the first quarter of 2014, the company reported a net loss of $16.1 million, or $0.17 per share, compared with a net loss of $11.7 million, or $0.14 per share, in the same period of 2013. It reported an increase in research and development expenses to $12.8 million in the first quarter, compared with $8.7 million for the same period of 2013, primarily due to increased preclinical and manufacturing costs for ACH-3422, combined with increased clinical development costs for ACH-3102 and ACH-2684, according to a statement.

Shares of the company traded down 2.11% to $7.43 on Wednesday. It has a 52 week high of $8.61 and a 52 week low of $2.26. Analysts have the consensus average target price of $10.00 for the stock. The consensus average recommendation is ‘overweight’.

Other significant shareholders of the company include Daniel Gold’s QVT Financial, which holds 10.82 million shares, and Kevin Kotler’s Broadfin Capital, which owns 1.0 million shares.

Boston-based RA Capital invests in companies with promising drugs and technologies. At the end of first quarter of 2014, the value of the fund’s equity portfolio was $1.4 billion. The largest holding was represented by Sangamo Biosciences Inc. (NASDAQ:SGMO), in which RA Capital disclosed ownership of 5.22 million shares. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) is another important holding, in which the fund revealed holding 2.43 million shares.

Disclosure: none

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!